Buy Or Sell Opportunity • Aug 07
Now 22% undervalued Over the last 90 days, the stock has risen 27% to ₩8,630. The fair value is estimated to be ₩11,067, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 3.5% over the last 3 years. Earnings per share has grown by 33%. New Risk • May 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (₩139.6b market cap, or US$94.6m). Reported Earnings • Mar 24
Full year 2025 earnings released: ₩731 loss per share (vs ₩279 loss in FY 2024) Full year 2025 results: ₩731 loss per share (further deteriorated from ₩279 loss in FY 2024). Revenue: ₩287.5b (down 9.6% from FY 2024). Net loss: ₩15.0b (loss widened 161% from FY 2024). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Tillkännagivande • Mar 12
Cosmax Nbt, Inc., Annual General Meeting, Mar 27, 2026 Cosmax Nbt, Inc., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 127-16, deokpyeong-ro 663beon-gil, gyeonggi-do, icheon South Korea New Risk • Jul 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (₩89.6b market cap, or US$64.9m). Reported Earnings • Mar 20
Full year 2024 earnings released: ₩279 loss per share (vs ₩314 loss in FY 2023) Full year 2024 results: ₩279 loss per share (improved from ₩314 loss in FY 2023). Revenue: ₩318.0b (down 4.7% from FY 2023). Net loss: ₩5.75b (loss narrowed 11% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings. Tillkännagivande • Mar 08
Cosmax Nbt, Inc., Annual General Meeting, Mar 26, 2025 Cosmax Nbt, Inc., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 127-16, deokpyeong-ro 663beon-gil, majang-myeon, gyeonggi-do, icheon South Korea New Risk • Sep 17
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩62.8b market cap, or US$47.7m). Buy Or Sell Opportunity • Aug 07
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 32% to ₩3,040. The fair value is estimated to be ₩3,812, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.6% over the last 3 years. Earnings per share has declined by 19%. Price Target Changed • Jul 03
Price target increased by 29% to ₩10,500 Up from ₩8,150, the current price target is provided by 1 analyst. New target price is 166% above last closing price of ₩3,940. Stock is down 35% over the past year. The company is forecast to post earnings per share of ₩747 next year compared to a net loss per share of ₩315 last year. Reported Earnings • Mar 21
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: ₩314 loss per share (improved from ₩633 loss in FY 2022). Revenue: ₩333.6b (up 1.7% from FY 2022). Net loss: ₩6.49b (loss narrowed 50% from FY 2022). Revenue missed analyst estimates by 3.0%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 8.8% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Personal Products industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 15% per year whereas the company’s share price has fallen by 18% per year. New Risk • Jan 31
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩129.7b (US$97.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company. New Risk • Nov 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Reported Earnings • Mar 26
Full year 2022 earnings released: ₩633 loss per share (vs ₩309 loss in FY 2021) Full year 2022 results: ₩633 loss per share (further deteriorated from ₩309 loss in FY 2021). Revenue: ₩328.2b (up 13% from FY 2021). Net loss: ₩13.1b (loss widened 104% from FY 2021). Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Buying Opportunity • Nov 30
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 19%. The fair value is estimated to be ₩5,427, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 43%. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 3 highly experienced directors. No independent directors (3 non-independent directors). Director Eun-Il Han was the last director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). Director Eun-Il Han was the last director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Price Target Changed • May 13
Price target increased to ₩14,000 Up from ₩12,000, the current price target is an average from 2 analysts. New target price is 33% above last closing price of ₩10,500. Stock is up 111% over the past year. Is New 90 Day High Low • Feb 26
New 90-day low: ₩7,410 The company is down 5.0% from its price of ₩7,800 on 27 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 13% over the same period. Is New 90 Day High Low • Nov 16
New 90-day low: ₩7,890 The company is down 13% from its price of ₩9,040 on 18 August 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩10,616 per share. Is New 90 Day High Low • Oct 26
New 90-day low: ₩7,970 The company is down 2.0% from its price of ₩8,170 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩12,583 per share. 
